Vivos Inc. announced a record-breaking first quarter for its IsoPet Animal Cancer Division in Q1 2025, with a 150% year-over-year increase in treatment volume. The company treated 15 pets during this period, demonstrating growing adoption of its Precision Radionuclide Therapy. This surge in volume is supported by a biweekly production schedule ensuring a steady supply of yttrium-90 hydrogel.
IsoPet achieved groundbreaking advancements in equine oncology, treating four horses with ocular squamous cell carcinoma, including two with direct cornea injections. This novel approach addresses a condition with limited treatment options. Additional applications included palliative therapy for advanced equine jaw cancer and margin therapy post-tumor resection.
Vivos Inc. activated three new certified clinics in Q1 2025, bringing the total to 14, comprising 8 small animal and 6 equine facilities. New additions include Brazos Equine Hospital in Texas, Sumner Veterinary Hospital in Washington, and Animal Emergency & Specialty Center in Tennessee. The company aims to expand its clinic network across the USA in 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.